非酒精性脂肪性肝病更名带来的新思考

高鑫

doi:10.3969/j.issn.1001-5256.2020.06.001

非酒精性脂肪性肝病更名带来的新思考

DOI: 10.3969/j.issn.1001-5256.2020.06.001

高鑫

复旦大学附属中山医院内分泌科

详细信息

中图分类号: R575.5
计量
- 文章访问数: 1376
- HTML全文浏览量: 41
- PDF下载量: 451
- 被引次数: 0
出版历程
- 出版日期: 2020-06-20

New thoughts about renaming nonalcoholic fatty liver disease

Gao Xin

摘要

摘要:
非酒精性脂肪性肝病(NAFLD)是一种代谢紊乱相关的多系统疾病,在肥胖和2型糖尿病(T2DM)患者中更为常见,而且与这两个共患疾病有着相似的不良结局。长期以来,NAFLD的重点强调肝脏病变和肝病相关结局,内分泌科医生按照目前糖尿病临床指南处理T2DM的同时往往忽视了对肝脏病变的筛查、诊断与处理。因此,在实际工作中,将NAFLD更名为代谢相关脂肪性肝病有着重要的现实意义。以降低肝脂肪含量为目标的防治T2DM的策略需要多学科临床与基础合作,以共同理念防治肥胖、脂肪肝、糖尿病,才能将最常见的慢性病防治落到实处。
- 非酒精性脂肪性肝病 /
- 代谢相关脂肪性肝病 /
- 科学术语(主题)
Abstract:
Nonalcoholic fatty liver disease( NAFLD) is a multisystem disease involving metabolic disorder and is more common in patients with obesity and type 2 diabetes mellitus( T2 DM),with similar adverse outcomes to these two comorbidities. For a long time,NAFLD has emphasized liver lesions and outcomes of liver diseases,and when treating T2 DM according to the current clinical guidelines for diabetes,endocrinologists often neglect the screening,diagnosis,and treatment of liver lesions. Therefore,in clinical practice,NAFLD renamed as metabolic-associated fatty liver disease has important practical significance. Strategies for T2 DM prevention and treatment aiming at reducing liver lipid content require multidisciplinary cooperation,and prevention and treatment of obesity,fatty liver disease,and diabetes with the same concepts can help to implement the prevention and treatment of the most common chronic diseases.
- non-alcoholic fatty liver disease /
- metabolic associated fatty liver disease /
- terminology as topic

HTML全文

参考文献(24)

[1] ESLAM M,NEWSOME PN,SARIN SK,et al. A new definition for metabolic dysfunction-associated fatty liver disease:An international expert consensus statement[J]. J Hepatol,2020.[Online ahead of print]

[2] LI J,ZOU B,YEO YH,et al. Prevalence,incidence,and outcome of non-alcoholic fatty liver disease in Asia,1999-2019:A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2019,4(5):389-398.

[3] FRIEDMAN SL,NEUSCHWANDER-TETRI BA,RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018,24(7):908-922.

[4] MOHAMMED E,ARUN JS,JACOB G,et al. MAFLD:A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology,2020,158(7):1999-2014.

[5] GASTALDELLI A,CUSI K. From NASH to diabetes and from diabetes to NASH:Mechanisms and treatment options[J].JHEP Rep,2019,1(4):312-328.

[6] AMARAPURKAR DN,HASHIMOTO E,LESMANA LA,et al.How common is non-alcoholic fatty liver disease in the AsiaPacific region and are there local differences?[J]. J Gastroenterol Hepatol,2007,22(6):788-793.

[7] POLYZOS SA,KOUNTOURAS J,MANTZOROS CS. Obesity and nonalcoholic fatty liver disease:From pathophysiology to therapeutics[J]. Metabolism,2019,92:82-97.

[8] BRIL F,CUSI K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes:A call to action[J]. Diabetes Care,2017,40(3):419-430.

[9] BRIL F,CUSI K. Nonalcoholic fatty liver disease:The new complication of type 2 diabetes mel itus[J]. Endocrinol Metab Clin North Am,2016,45(4):765-781.

[10] MARCHESINI G,DAY CP,DUFOUR JF,et al. EASL-EASDEASO clinical practice guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol,2016,64(6):1388-1402.

[11] Chinese Society of Endocrinology,Chinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders(2nd Edition)[J].J Clin Hepatol,2018,34(10):2103-2108.(in Chinese)中华医学会内分泌学分会．非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版)[J]．临床肝胆病杂志，2018,34(10):2103-2108.

[12] BIAN H,ZHU X,XIA M,et al. Impact of type 2 diabetes on nonalcoholic steatohe patitis and advanced fibrosis in patients with nonalcoholic fatty liver disease[J]. Endocr Pract,2020,26(4):444-453.

[13] PORIES WJ,MACDONALD KG Jr,MORGAN EJ,et al. Surgical treatment of obesity and its effect on diabetes:10-y follow-up[J]. Am J Clin Nutr,1992,55(2 Suppl):582s-585s.

[14] LEAN ME,LESLIE WS,BARNES AC,et al. Primary care-led weight management for remission of type 2 diabetes(DiRECT):An open-label,cluster-randomised trial[J]. Lancet,2018,391(10120):541-551.

[15] LEAN M,LESLIE WS,BARNES AC,et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes:2-year results of the DiRECT openlabel,cluster-randomised trial[J]. Lancet Diabetes Endocrinol,2019,7(5):344-355.

[16] TAYLOR R,AL-MRABEH A,SATTAR N. Understanding the mechanisms of reversal of type 2 diabetes[J]. Lancet Diabetes Endocrinol,2019,7(9):726-736.

[17] TAYLOR R,BARNES AC. Can type 2 diabetes be reversed and how can this best be achieved? James Lind Alliance research priority number one[J]. Diabet Med,2019,36(3):308-315.

[18] PETRICK JL,KELLY SP,ALTEKRUSE SF,et al. Future of hepatocellular carcinoma incidence in the united states forecast through 2030[J]. J Clin Oncol,2016,34(15):1787-1794.

[19] HESTER D,GOLABI P,PAIK J,et al. Among medicare patients with hepatocellular carcinoma,non-alcoholic fatty liver disease is the most common etiology and cause of mortality[J]. J Clin Gastroenterol,2020,54(5):459-467.

[20] ANSTEE QM,REEVES HL,KOTSILITI E,et al. From NASH to HCC:Current concepts and future challenges[J]. Nat Rev Gastroenterol Hepatol,2019,16(7):411-428.

[21] FRIEDMAN SL,NEUSCHWANDER-TETRI BA,RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018,24(7):908-922.

[22] ALUKAL JJ,THULUVATH PJ. Reversal of NASH fibrosis with pharmacotherapy[J]. Hepatol Int,2019,13(5):534-545.

[23] FIORUCCI S,BIAGIOLI M,DISTRUTTI E. Future trends in the treatment of non-alcoholic steatohepatitis[J]. Pharmacol Res,2018,134:289-298.

[24] JOHNSTON MP,PATEL J,BYRNE CD. Multi-drug approaches to NASH:What's in the development pipeline?[J]. Expert Opin Investig Drugs,2020,29(2):143-150.

施引文献

资源附件(0)

访问统计